Ferro, Albert
Albert Ferro researcher
VIAF ID: 315227581 (Personal)
Permalink: http://viaf.org/viaf/315227581
Preferred Forms
- 100 0 _ ‡a Albert Ferro ‡c researcher
-
- 100 1 _ ‡a Ferro, Albert
-
-
-
- 100 1 _ ‡a Ferro, Albert
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
100 cases in clinical pharmacology, therapeutics and prescribing | |
Antiplatelet and Anticoagulation Therapy | |
Antiplatelet drug resistance: Molecular insights and clinical implications | |
Aspirin-induced histone acetylation in endothelial cells enhances synthesis of the secreted isoform of netrin-1 thus inhibiting monocyte vascular infiltration. | |
Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment | |
Beta-adrenergic receptors and nitric oxide generation in the cardiovascular system. | |
beta-adrenoceptors and potassium channels | |
Biological therapies: a long way on from Jenner | |
Cardiac effects of amiloride and of enalapril in the spontaneously hypertensive rat. | |
Cardiac stem cell therapy: present and future | |
Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress | |
Changes in C-reactive protein in response to anti-inflammatory therapy as a predictor of cardiovascular outcomes: A systematic review and meta-analysis | |
Clinical pharmacology: a declaration of intent | |
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications | |
Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation. | |
CXCR2 Inhibition - a novel approach to treating CoronAry heart DiseAse (CICADA): study protocol for a randomised controlled trial | |
Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension | |
Drugs for addiction: a therapeutic area in need of a 'shot in the arm'. | |
Editors' pick 2014. | |
Editors' Report, November 2009. | |
The effect of aspirin on circulating netrin-1 levels in humans is dependent on the inflammatory status of the vascular endothelium | |
The effectiveness of a specialist Hypertension Clinic in reducing blood pressure: Factors determining blood pressure response | |
Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases | |
Endothelial function and arterial compliance are not impaired in subjects with heart failure of non-ischemic origin | |
Erectile dysfunction in diabetes: 'NO' role for the endothelium? | |
Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. | |
From an evolutionary perspective, all 'new' antimicrobial targets are old: time to think outside the box. | |
Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment. | |
Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society | |
Hydrogen Sulfide Donor GYY4137 Protects against Myocardial Fibrosis. | |
Hydrogen Sulfide Induces Keap1 S-sulfhydration and Suppresses Diabetes-Accelerated Atherosclerosis via Nrf2 Activation. | |
Hydrogen Sulfide Regulates Krüppel-Like Factor 5 Transcription Activity via Specificity Protein 1 S-Sulfhydration at Cys664 to Prevent Myocardial Hypertrophy. | |
Importance of renin in blood pressure regulation and therapeutic potential of renin inhibition. | |
Increased expression of integrin-linked kinase improves cardiac function and decreases mortality in dilated cardiomyopathy model of rats | |
Increased platelet aggregation in vivo in the Zucker Diabetic Fatty rat: differences from the streptozotocin diabetic rat | |
Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects | |
Increased salience of gains versus decreased associative learning differentiate bipolar disorder from schizophrenia during incentive decision making. | |
Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes | |
Lower, faster, better: the delusions of surrogate markers in hypertension | |
Mechanisms underlying beta2-adrenoceptor-mediated nitric oxide generation by human umbilical vein endothelial cells | |
Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes. | |
Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts | |
Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes | |
Netrin-1 as a novel therapeutic target in cardiovascular disease: to activate or inhibit? | |
Neurohormony a niewydolność serca | |
Newer antiplatelet agents in acute coronary syndrome | |
Nitric oxide generation mediated by beta-adrenoceptors is impaired in platelets from patients with Type 2 diabetes mellitus | |
Noninvasive MRI monitoring of the effect of interventions on endothelial permeability in murine atherosclerosis using an albumin-binding contrast agent | |
Nutraceuticals: is there good science behind the hype? | |
Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events | |
Organised crime against the academic peer review system. | |
Paediatric prescribing: why children are not small adults | |
Pharmacogenetics of aspirin resistance: a comprehensive systematic review | |
The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis | |
Platelet activation in essential hypertension: implications for antiplatelet treatment | |
Platelet-derived microparticles are implicated in remote ischemia conditioning in a rat model of cerebral infarction | |
Platelet-derived nitric oxide signaling and regulation. | |
Pyridoxine increases nitric oxide biosynthesis in human platelets | |
Pyridoxine inhibits endothelial NOS uncoupling induced by oxidized low-density lipoprotein via the PKCα signalling pathway in human umbilical vein endothelial cells. | |
Rabbit aortic endothelial dysfunction by low-density lipoprotein is attenuated by L-arginine, L-ascorbate and pyridoxine. | |
Renal denervation as an option for the management of hypertension | |
Renal dopamine receptors and hypertension | |
Renin inhibitors: An important advance in hypertension treatment? | |
The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials | |
S-nitrosophytochelatins: investigation of the bioactivity of an oligopeptide nitric oxide delivery system | |
SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. | |
SNO-MLP (S-Nitrosylation of Muscle LIM Protein) Facilitates Myocardial Hypertrophy Through TLR3 (Toll-Like Receptor 3)-Mediated RIP3 (Receptor-Interacting Protein Kinase 3) and NLRP3 (NOD-Like Receptor Pyrin Domain Containing 3) Inflammasome Activat | |
Statins and vascular protection: a 'radical' view | |
Syndecan-4 over-expression preserves cardiac function in a rat model of myocardial infarction. | |
l-Tetrahydropalmatine, an active component of Corydalis yanhusuo W.T. Wang, protects against myocardial ischaemia-reperfusion injury in rats. | |
Traditional Chinese medicines in the management of cardiovascular diseases: a comprehensive systematic review | |
Whole body nitric oxide production is not decreased in patients with coronary atherosclerosis but is inversely related to plasma homocysteine | |
Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization | |
β-catenin promotes endothelial survival by regulating eNOS activity and flow-dependent anti-apoptotic gene expression |